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The treatment of hepatitis C virus (HCV) has made signiﬁcant
advances with the development of new direct-acting antivirals.
Nucleotide polymerase inhibitors are one class of these newmed-
ications that have been shown to be highly effective, safe and
well tolerated as part of an antiviral regimen. Sofosbuvir has
become the ﬁrst drug in this class to be approved for clinical
use, supported by results from extensive phase II and phase III
clinical trials. This review will further discuss nucleotide poly-
merase inhibitors, including the data supporting their use as part
of interferon-free HCV treatment regimens.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Hepatitis C virus (HCV) is a major cause of chronic liver disease
worldwide, affecting both industrialized and developing coun-
tries. Over 170 million patients worldwide are infected and of
those, many will develop cirrhosis [1–3], with its attendant risk
of life-threatening complications [4]. For a decade, pegylated
interferon (PegIFN) and ribavirin (RBV) were the foundation of
hepatitis C treatment. However, with suboptimal rates of
sustained virologic response (SVR), signiﬁcant side effects, and
protracted treatment duration of the interferon-based therapy,
alternative approaches have long been the goal. Further investi-
gation of the HCV life cycle has facilitated the development of
novel drugs, including several classes of direct-acting antiviral
agents (DAAs) that target the NS3/4A protease, NS5B RNA-depen-
dent RNA polymerase, and the NS5A serine protease [5,6]. The
ﬁrst of the DAAs to be used in routine clinical practice were theJournal of Hepatology 20
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to the regimen of genotype 1 HCV treatment in 2011. Both
increased the SVR rate of HCV treatment, but at the cost of side
effects beyond those of PegIFN and RBV alone, especially in
patients with more advanced ﬁbrosis [7–9]. Only three years after
the approval of these protease inhibitors, their use has essentially
ceased in many countries with the introduction of PegIFN based
regimens containing the nucleotide analogue sofosbuvir (SOF),
or the protease inhibitor simeprevir (SIM), for genotype 1
patients and the actual or anticipated advent of highly effective,
well tolerated interferon-free DAA combination regimens. All-
oral regimens of SOF and RBV for patients with genotypes 2
and 3 infection have also been implemented. This review will
focus on regimens containing nucleotide polymerase inhibitors,
with a focus on SOF, the ﬁrst approved drug in this class. Another
review in this volume focuses on non-nucleotide regimens, which
also have demonstrated very high rates of efﬁcacy.
The NS5B polymerase is a fundamental enzyme, involved in
HCV replication by catalysing the replication of the viral RNA gen-
ome. Drugs acting on the NS5B polymerase are classiﬁed as either
nucleoside/nucleotide or non-nucleos(t)ide inhibitors. Non-
nucleos(t)ide inhibitors bind to sites remote from the active cata-
lytic site, causing conformational changes in the protein. Nucleo-
side/nucleotide analogues, on the other hand, mimic the natural
substrate of the NS5B protein, leading to termination of the nas-
cent RNA chain [10]. The highly conserved active site of the HCV
polymerase contributes to two important properties of nucleotide
polymerase inhibitors: they are effective across all genotypes and,
because of the deleterious consequences of mutations on the rep-
licative ﬁtness of resultant variants, they have a high barrier to
resistance,making this class an extremely attractive potential cor-
nerstone for DAA regimens [11].
One of the initial NS5B polymerase inhibitors to be studied
was a uridine nucleotide analogue, mericitabine (RG7128), which
was found to decrease HCV RNA in a dose escalating phase 1b
trial in genotype 1 patients [12]. Mericitabine continued to be
studied as part of a regimen with PegIFN and RBV with promising
results in genotype 1–3 patients [13,14]. The ﬁrst proof of con-
cept study of oral combination therapy with NS5B polymerase
inhibitors was with the INFORM-1 study, carried out in Australia
and New Zealand, where mericitabine, when combined with a
protease inhibitor (danoprevir) for two weeks, resulted in potent
viral suppression in both treatment-naïve and previous null
responders [15]. Despite its historic role as a component of this14 vol. 61 j S91–S97
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proof of concept regimen and its safety and resistance barrier in
subsequent clinical trials of both interferon-containing and inter-
feron-free regimens, mericitabine was associated with subopti-
mal rates of sustained virologic response. Other nucleotide
analogues, including R1626 and INX-189, met unfortunate ends
because of unexpected safety problems. In contrast, the develop-
ment of SOF, a uridine analogue, was marked by compelling efﬁ-
cacy and safety data, culminating in its approval by the United
States Food and Drug Administration (FDA) and the European
Medicines Agency (EMA) as a component of antiviral regimens.
Other nucleos(t)ide analogues continue to move forward in
development that may eventually provide additional treatment
options for patients. Although mericitabine has been moderately
successful in interferon-containing and interferon-free regimens,
due to the higher efﬁcacy of SOF, it is unlikely to play a role in
HCV treatment. VX-135 is another nucleotide analogue that has
been studied in combination with RBV in phase 1 and 2a studies.
ACH3422, another uridine analogue, is currently undergoing
phase 1 testing, along with IDX21437, which was recently shown
to have a favourable preclinical proﬁle [16].
Sofosbuvir has been studied in several thousand patients,
including thosewith cirrhosis and thosewith decompensated liver
disease awaiting liver transplant [17], and since its approval it has
been used to treat many more thousand patients. The standard
dose of SOF is 400 mg once daily, with no dose adjustments neces-
sary for hepatic or renal impairment (as long as the glomerular ﬁl-
tration rate [GFR] is over 30). The drug is absorbed intact through
the gastrointestinal tract leading to high liver exposure and no sig-
niﬁcant food effect and its predominant metabolite is then renally
excreted [18,19]. There are low rates of drug-drug interactions as
the metabolism is not linked to the CYP3A4 pathway [19].
Key Points
• Nucleotide polymerase inhibitors combine potency with 
pan-genotypic activity and a high barrier to resistance, 
making them appealing as a backbone for combination 
antiviral regimens
• Sofosbuvir has become the first NS5B nucleotide 
polymerase inhibitor to be approved for use in clinical 
practice
• Based on demonstrated efficacy and safety, sofosbuvir 
has been approved for use in combination with ribavirin 
for HCV genotypes 2 and 3, and in combination with 
pegylated interferon and ribavirin in genotype 1
• Recent phase II and III studies have supported the use 
of sofosbuvir as part of an interferon-free regimen for 
genotype 1 HCVGenotype 1
Following the initial monotherapy studies with sofosbuvir, dem-
onstrating marked viral suppression across HCV genotypes
[20,21], the phase 2 program evaluated the combination of SOF
with PegIFN and RBV as well as the use of SOF in interferon-free
regimens. In genotype 1 patients treated with PegIFN, RBV and
SOF (PR/SOF), SVR rates of 87–92% were attained [22,23]. Most
notably, the ATOMIC study contained one arm of 52 genotype 1S92 Journal of Hepatology 201patients who received PR/SOF for only 12 weeks with a SVR rate
of 90% [22]. These results prompted the single-arm, open-label
phase 3 NEUTRINO study, which evaluated, and subsequently
led to the regulatory approval of, PR/SOF for 12 weeks in patients
with HCV genotype 1, 4, 5, or 6 [24]. Two hundred ninety-two
genotype 1 patients were enrolled, of whom 89% achieved SVR,
92% in genotype 1a and 82% in genotype 1b. Seventeen percent
of the genotype 1 patients had compensated cirrhosis, with a
SVR of 80%, compared to 92% in the non-cirrhotic group. With
the adverse event proﬁle of this regimen indistinguishable from
that of PR alone and only 2% of patients discontinuing treatment
due to adverse events, the efﬁcacy and short duration of therapy
established what could be considered a ‘‘new plateau’’ for inter-
feron-based therapy even though PegIFN will likely be phased
out in the near future.
One of the ﬁrst demonstrations of the efﬁcacy of an all oral
treatment regimen in genotype 1 patients with SOF was in a
cohort of the ELECTRON trial, demonstrating a SVR of 84% in 25
treatment-naïve patients treated for 12 weeks. However, only
10% (1/10) of null-responders achieved SVR after 12 weeks of
SOF and RBV [21], signaling an inability of the regimen to over-
come whatever host factors are encompassed by IFN failure that
might be needed to augment the response to a DAA regimen. The
same regimen in similar numbers of treatment-naïve patients
revealed SVR12 rates of 47% and 68% in two other studies
(QUANTUM and SPARE involving 12 and 24 weeks of treatment,
respectively) [25,26]. The few treatment-naïve cirrhotics in these
studies did not attain SVR, supporting the concept that advanced
ﬁbrosis also impacts treatment success [26]. The only completed
phase 3 trial that further evaluated the combination of SOF and
RBV in genotype 1 (and other) patients was the PHOTON study,
which consisted of treatment naïve patients with HIV–HCV
coinfection, of whom less than 10% had cirrhosis [27]. Of the
114 patients, 76% had SVR. Based on these data, the label for
SOF in both the U.S. and Europe allows for the administration
of SOF and RBV for 24 weeks to interferon ineligible patients with
genotype 1. However, with SVR rates lower than those attainable
with DAA combinations, even in non-cirrhotic treatment-naïve
genotype 1 patients, this regimen is being used uncommonly.
Given the diverse mechanisms of action and unique targets of
the direct-acting antivirals, combinations of other DAAs with SOF
have been studied and have provided superior results, including
treatment of patient populations that are typically thought of
being harder to treat. The NS5A protein, for example, is a 447
amino acid phosphoprotein essential for RNA replication that
has become another target of direct-acting antivirals. Drugs in
the NS5A inhibitor class have been termed ‘‘replication complex
inhibitors’’ to which at least two characteristics have been attrib-
uted: the inhibition of viral RNA synthesis and virion assembly
and secretion [28]. These drugs are highly potent but have a rel-
atively low barrier to resistance when administered as single
agents. Daclatasvir (DCV) was shown in a landmark phase 2 study
to effect SVR in an extraordinarily high proportion of genotype 1
patients. After an initial exploratory cohort of treatment-naïve
patients were treated with 24 weeks of DCV plus SOF with or
without RBV, including some with a seven day lead-in of SOF,
82 non-cirrhotic treatment-naïve genotype 1 patients were trea-
ted for 12 weeks, with or without RBV, and 41 patients who had
failed therapy with a protease inhibitor were treated for
24 weeks [28]. All but three of the patients (two naïve, one expe-
rienced) had SVR12, of whom two had unavailable SVR12 data4 vol. 61 j S91–S97
Table 1. Summary of ION 1-3 trials.
Study Population Treatment* Duration
(wk) 
Overall SVR 12 SVR by cirrhosis
No Yes
ION-1 [32] 
(n = 865) 
GT-1 
Treatment-naïve  
(15.7% with cirrhosis) 
SOF/LDV 12 99% (211/214) 99% (179/180)  94% (32/34)
SOF/LDV + RBV 12 97% (211/217) 97% (178/184) 100% (33/33)
SOF/LDV 24 98% (212/217) 98% (181/184)  94% (31/33)
SOF/LDV + RBV 24 99% (215/217) 99% (179/181) 100% (36/36)
ION-2 [33] 
(n = 440) 
GT-1 
Treatment-experienced 
(20.0% with cirrhosis) 
SOF/LDV 12 94% (102/109) 95% (83/87) 86% (19/22)
SOF/LDV + RBV 12 96% (107/111) 100% (89/89) 82% (18/22)
SOF/LDV 24 99% (108/109) 99% (86/87) 100% (22/22)
SOF/LDV + RBV 24 99% (110/111) 99% (88/89) 100% (22/22)
ION-3 [35] 
(n = 647) 
GT-1 
Treatment-naïve 
(0.0% with cirrhosis) 
SOF/LDV 8 94% (202/215) 94% (202/215)
SOF/LDV + RBV 8 93% (201/216) 93% (201/216)
SOF/LDV 12 95% (206/216) 95% (206/216)
⁄Daily dosing as follows: sofosbuvir – 400 mg; ledipasvir – 90 mg, ribavirin – 1000 mg if <75 kg, 1200 mg if P75 kg.
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JOURNAL OF HEPATOLOGYbut achieved SVR24, while the third was lost to follow-up.
Consistent with the lack of cross resistance between the NS5A
and protease inhibitor classes, the presence of protease inhibitor
resistant variants at baseline had no impact on treatment out-
come. Additionally, there has been a case report of a single
patient with severe recurrent cholestatic HCV after liver
transplantation being successfully treated with DCV and SOF for
24 weeks, prompting further treatment of patients with
advanced cirrhosis with this combination through a recently
established compassionate use program [29]. Although not
currently widely available, DCV is expected to be FDA approved
in the near future, and at that point the combination may become
accessible to a larger audience.
Additional arms of the ELECTRON trial showed that the
combination of SOF, ledipasvir (LDV, another NS5A inhibitor) with
or without RBV given for 12 weeks yielded 95–100% SVR rates in
treatment-naïve patients, previous null-responders, and patients
who had failed prior treatment with protease inhibitors [30].
The phase 2 LONESTAR study further ampliﬁed the results seen
in the ELECTRON trial with a cohort of 40 patients who had
previously failed a regimen with a protease inhibitor, half with
cirrhosis, receiving the same regimen [31]. SVR12 was achieved
by 95% of those without RBV and by 100% of those with RBV. In
other cohorts of the LONESTAR study intended to evaluate the
efﬁcacy of an eight week regimen of SOF and LDV, SVR12 was
achieved by 95% of those in the 8 week arm without RBV, by
100% in the 8 week armwith RBV, and by 95% in the 12 week arm.
The results of the phase 2 trials led to three large phase 3
trials, further evaluating SOF and LDV in a single ﬁxed-dose com-
bination pill, administered once daily across a broad spectrum of
a large numbers of patients, with the opportunity to compare dif-
ferent durations of therapy and the need for ribavirin (Table 1).
ION-1 randomized treatment-naïve patients to receive treatment
for 12 or 24 weeks, with or without RBV [32]. The study included
865 patients, 67% with genotype 1a infection and 16% with cir-
rhosis. SVR12 was 99% in the group that received 12 weeks of
SOF and LDV without RBV and 97% in the group with RBV. In
the 24 week treatment groups, SVR12 was 98–99% [32]. Within
the 12 week arm, patients without cirrhosis had a SVR rate of
99% without RBV and 97% with RBV, compared to 94% and
100%, respectively in patients with cirrhosis. In the 24 week
treatment arm, patients without cirrhosis had 98% SVR withoutJournal of Hepatology 201RBV and 99% SVR12 with RBV, compared to 94% and 100%,
respectively in patients with cirrhosis. Notably, only one patient
had on-treatment virologic breakthrough, likely due to non-
adherence, and only two had post-treatment relapse. All other
patients who failed to attain SVR were either lost to follow-up
or withdrew from the study. ION-2 had an identical study design
but evaluated patients who had previously failed interferon
based treatment, with or without a protease inhibitor. Results
demonstrated high SVR rates across all treatment groups. The
12 week group had SVR rates of 96% and 94% with and without
RBV, respectively and both 24 week treatment groups had 99%
SVR rates [33]. A history of protease inhibitor failure had no
impact on the outcomes, conﬁrming the phase 2 observations.
Of the 88 cirrhotic patients (22 in each arm), SVR12 was
82–86% in the 12 week arms (higher without RBV) and 100% in
both 24 week arms. The primary publication of this study
indicated that the difference in outcomes between the 12 and
24 week-treated cirrhotic patients had a p value of 0.007, but also
states that the study was not powered to make the comparison.
Overall, it seems likely that physicians and patients will prefer
a 24 week regimen of LDV and SOF for treatment-experienced
cirrhotic patients. Additional data suggesting that patients with
advanced liver disease will require a longer duration of therapy
comes from a pilot study of LDV and SOF, in which only 65% of
patients treated for 12 weeks attained SVR [34].
The third phase 3 trial of SOF and LDV (ION-3) was designed
to further explore a shortened duration of therapy, founded upon
the high SVR rates in patients of the LONESTAR study who had
received only 8 weeks of treatment. Treatment-naïve non-
cirrhotic patients were randomized to receive LDV and SOF with
or without RBV for 8 weeks, or only LDV and SOF for 12 weeks.
The rate of SVR was 94% in the 8 week arm without RBV, 93%
with the addition of ribavirin. The 12 week arm had a 95% SVR
rate [35]. Relapse occurred in 9 and 11 patients (4% and 5%), with
and without RBV, respectively, in the 8 week arms vs. 3 patients
(1%) treated for 12 weeks. Still, the results of the study provide a
foundation for shortened treatment duration with LDV and SOF of
8 weeks with minimal impact on SVR rates and the capacity to
spare a very high proportion of patients the additional weeks of
treatment they may not require. The availability of data on
‘‘salvage regimens’’, perhaps consisting of readministration of a
24 week course of treatment or, alternatively, containing other4 vol. 61 j S91–S97 S93
Table 2. Summary of the phase 3 trials for HCV genotype 2 and 3.
Study Population Treatment* Duration
(wk) 
Overall SVR 12 SVR by cirrhosis
No Yes
FISSION [24]
(n = 499)
GT-2: Treatment-naïve SOF/RBV 12 97% (68/70) 97% (68/70) 91% (10/11)
PEG/RBV 24 78% (52/67) 81% (44/54) 62% (8/13)
GT-3: Treatment-naive SOF/RBV 12 56% (102/183) 61% (89/145) 34% (13/38)
PEG/RBV 24 62% (110/176) 71% (99/139) 30% (11/37)
POSITRON [39] 
(n = 278) 
GT-2: IFN ineligible, 
intolerant or unwilling
SOF/RBV 12 93% (101/109) 92% (85/92) 94% (16/17)
Placebo 12 0% 0% 0%
GT-3: IFN ineligible, 
intolerant or unwilling
SOF/RBV 12 61% (60/98) 68% (57/84) 21% (3/14)
Placebo 12 0% 0% 0%
FUSION [39]
(n = 201) 
GT-2: IFN non-responders SOF/RBV 12 86% (31/36) 96% (25/26) 60% (6/10)
SOF/RBV 16 94% (30/32) 100% (23/23) 78% (7/9)
GT-3: IFN non-responders SOF/RBV 12 30% (19/64) 37% (14/38) 19% (5/26)
SOF/RBV 16 62% (39/63) 62% (25/40) 61% (14/23)
VALENCE [40]
(n = 419)
GT-2: Naïve SOF/RBV 12 97% (31/32) 97 % (29/30) 100% (2/2)
Non-responders 90% (37/41) 94% (30/32) 78% (7/9)
GT-3: Naïve SOF/RBV 24 94% (99/105) 95% (87/92) 92% (12/13)
Non-responders 79% (114/145) 87% (85/98) 62% (29/47)
⁄Daily dosing as follows: sofosbuvir – 400 mg; ribavirin – 1000 mg if <75 kg, 1200 mg if P75 kg.
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Journal of Hepatology Update: Hepatitis Cagents, would enhance clinicians’ conﬁdence in administering
shorter treatment durations that may carry a slightly higher risk
of relapse.
Patients with characteristics historically associated with
poorer response to interferon based therapy, including cirrhosis,
genotype 1a subtype, non-CC IL28B allele, and blacks all still
had SVR rates over 90% in all of the aforementioned phase 3 stud-
ies. Using deep sequencing, baseline NS5A resistance was
detected in 14–18% of patients. In the ION-1 study, 96% of
patients with resistance achieved SVR, 89% in ION-2 and 90% in
ION-3. Baseline NS5A resistance variants tended to be present
more commonly among patients with virologic failure than in
the overall study populations. Nevertheless the high success rates
even in the setting of baseline resistant variants appears to limit
the role of baseline testing in clinical practice.
The approval of the second generation protease inhibitor,
simeprevir (SIM), has allowed practitioners in the United States
to treat patients with an interferon-free regimen of SIM in combi-
nation with SOF. The basis for the use of this combination is the
phase 2 COSMOS trial, an open label study investigating the safety
and efﬁcacy of the two drugs, with or without RBV for either 12 or
24 weeks. The ﬁrst cohort enrolled 80 genotype 1 previous null-
responders to treatment with PegIFN and RBV with a METAVIR
F0-F2 ﬁbrosis score [36]. In this group, the 12 week arm had
SVR12 by intent-to-treat analysis of 96% with RBV and 93% with-
out RBV. The 24 week arm had a SVR12 of 79% with RBV (17% was
non-virologic failure) and 93% without RBV.
The second cohort of this trial was composed of 87 treatment-
naïve and prior null-responders, divided roughly equally between
METAVIR F3-F4 ﬁbrosis [37]. The overall SVR12 in the 12 week
arm was 93% with or without RBV, while in the 24 week arms
it was 93% and 100%, respectively. As in cohort 1, all patients
had HCV RNA below the limit of quantiﬁcation (25 IU/ml) by
week 4, with no impact on detectability at week 4 on the
outcome. All three relapsers in cohort 2, two of them cirrhotic
(one treatment-naïve, one treatment-experienced), receivedS94 Journal of Hepatology 20112 weeks of treatment, raising the possibility that 24 weeks
may confer slightly higher rates of SVR in cirrhotics. However,
the patient numbers in COSMOS were insufﬁcient to allow ﬁrm
conclusions to be drawn. Nearly half the patients with genotype
1a in the COSMOS study had the Q80K polymorphism. Of the 3
relapsers in cohort 1, all had Q80K, while in cohort 2, the 3 relaps-
ers had genotype 1a but only 1 of the 3 had Q80K. When non-
virologic failures were excluded from the analysis, patients with
genotype 1a and Q80K had a SVR12 rate of 89% in cohort 1 and
96% in cohort 2, compared with 100% and 95% of genotype 1a
patients without Q80K. The impact of Q80K is clearly of far lesser
magnitude, if it exists at all, when SIM is combined with SOF than
when it is combined with PegIFN and RBV. Further insights into
this question along with optimal duration of treatment may
emerge from ongoing phase 3 trials and shortly anticipated ‘‘real
world’’ data on this regimen. In the meantime clinicians must
decide whether to assess patients with genotype 1a for the pres-
ence of the Q80K polymorphism in the absence of data indicating
that its presence warrants a change in treatment strategy.
Patients offered this regimen, should be informed of its current
‘‘off-label’’ status, the size of the study on which it is based,
and the possibility of protease inhibitor resistance in the unlikely
event of virologic failure.Genotypes 2 and 3
The previous standard regimen for treatment of hepatitis C in
genotype 2 and 3 patients with PegIFN and RBV yielded SVR rates
of 70–85% [38]. However, the pan-genotypic effect of nucleotide
polymerase inhibitors has allowed SOF to be also successful as
the backbone of an interferon-free regimen for this patient popu-
lation (Table 2). The original arms of the ELECTRON trial initially
demonstrated the efﬁcacy of SOF and RBV in genotype 2 and 3
patients with 100% SVR12 in 10 patients treated for 12 weeks,
contrasting with SVR in 6 of 10 patients given SOF monotherapy4 vol. 61 j S91–S97
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[21]. The promising results prompted further phase 3 studies with
the same regimen. The FISSION trial randomized genotype 2 and 3
treatment-naïve patients to 12 weeks of SOF and RBV or the stan-
dard of care at that time (PEG and RBV for 24 weeks) [24]. Of the
499 patients enrolled, 20% had compensated cirrhosis, and 72%
had genotype 3 infection. 97% of the genotype 2 patients achieved
SVR12, compared to only 56% of the genotype 3 patients (78% and
63%, respectively in the standard of care arm), demonstrating a
striking difference in response between genotype 2 and 3 patients.
This study provided initial evidence for the need for different
treatment durations and/or regimens for the two genotypes.
Non-cirrhotic genotype 2 patients had a SVR rate of 98% compared
to 91% in those with cirrhosis. The impact of cirrhosis was far
more profound in genotype 3 patients, with SVR12 of 61% and
34%, respectively. In this and the other studies described here,
on-treatment viral kinetics were similar between the genotypes,
with failure almost always resulting from post-treatment relapse,
indicating greater difﬁculty in eradicating tissue reservoirs of
genotype 3 HCV compared to genotype 2 HCV.
The phase 3 POSITRON trial compared SOF and RBV for
12 weeks to placebo in genotype 2 and 3 patients who were
IFN intolerant, ineligible or unwilling [39]. The overall SVR12 in
the active treatment arm was 78%. However, there again was a
signiﬁcant distinction between the SVR12 in genotype 2 and 3
patients, with 93% in genotype 2 and 61% in genotype 3. Cirrhosis
also again was seen to be a predictor of poorer outcome, with
overall SVR 12 of 61%, 94% in genotype 2 and 21% in genotype 3.
The FUSION trial sought to evaluate whether extending dura-
tion of treatment would add any beneﬁt in patients who had
failed prior therapy [39]. This study compared 12 weeks to
16 weeks of SOF and RBV in 201 genotype 2 and 3 treatment-
experienced patients. SVR12 increased from 86% to 94% with
the extension of treatment in genotype 2 patients, and from
30% to 62% in genotype 3 patients. When evaluating only cir-
rhotic patients, SVR12 increased to 78% from 60% in genotype 2
patients with the additional month of treatment, but the small
patient numbers preclude deﬁnitive conclusions. In the genotype
3 cirrhotic group, SVR12 was 19% with 12 weeks and 61% with
16 weeks of treatment, a striking incremental beneﬁt resulting
from 4 additional weeks.
The VALENCE trial evaluated 12 weeks of SOF and RBV in
treatment-naïve and treatment-experienced patients with geno-
type 2 HCV and extended treatment to 24 weeks for genotype 3
patients [40]. Genotype 2 patients had 97–100% SVR12 in the
naïve group, 78% in treatment-experienced patients with cirrhosis
and 94% in treatment-experienced patients without cirrhosis. In
genotype 3 treatment-experienced patients, the SVR12 was 87%
in the non-cirrhotic population and 62% in cirrhotic patients. In
genotype 3 treatment-naïve patients, 95% of patients without
cirrhosis achieved SVR12 compared to 92% with cirrhosis. These
results led to the approval of SOF and RBV for 24 weeks in all
genotype 3 patients, although the results in treatment-
experienced genotype 3 cirrhotic patients did not exceed those
in the comparable patients in FUSIONwho received only 16 weeks
of treatment. Combined with the results of the other phase 3
trials, the approved treatment duration is 12 weeks in genotype 2.
With suboptimal rates of success with only SOF and RBV, the
LONESTAR-2 trial evaluated the utility of adding PegIFN to the
regimen. Forty seven treatment-experienced genotype 2 and 3
patients with or without compensated cirrhosis received PegIFN,
RBV and SOF for 12 weeks [41]. Genotype 2 patients had SVR12 ofJournal of Hepatology 20196% and genotype 3 patients had SVR12 of 83%. Among genotype
2 patients, all non-cirrhotics and all but 1 (93%) with cirrhosis
achieved SVR12. Among genotype 3 patients, the SVR12 rate
was 83% for both cirrhotics and non-cirrhotics. Recent data shed
further light on the potential for a persistent role of PegIFN by
showing that among patients with genotype 3 who had failed a
12–16 week regimen of SOF and RBV, a 12 week regimen of
PegIFN, RBV and SOF provided higher SVR rates, including in cir-
rhotics, than in patients retreated with 24 weeks of SOF and RBV
alone [42]. An ongoing trial comparing these two regimens will
provide further insights into the role, if any, for PegIFN, which
may currently remain a treatment option for some genotype 3
patients but will likely be rendered unnecessary by regimens
combining SOF with other direct-acting antivirals such as pan-
genotypic NS5A inhibitors [43].Genotypes 4, 5, and 6
Limited data exists on the use of SOF for other genotypes. The
NEUTRINO trial did have small numbers of genotype 4–6
patients, with 96% (27/28) of patients with genotype 4, the single
patient with genotype 5, and all six of the patients with genotype
6 achieving SVR [24]. The approval of SOF in combination with
PegIFN and RBV for 12 weeks also covers genotype 4 patients.
Additionally, a small study of Egyptian patients with genotype
4 in the United States demonstrated 79% (11/14) SVR in treat-
ment-naïve patients treated for 12 weeks with SOF and RBV
and 100% (14/14) SVR when treated for 24 weeks. In treatment-
experienced patients, SVR was 59% (10/17) with a 12 week treat-
ment duration and 87% (13/15) with 24 weeks [44]. Although
insufﬁcient numbers of genotype 5 and 6 patients were included
to garner regulatory approval, many clinicians would not hesitate
to treat such patients with the NEUTRINO regimen. Additionally
there has been some use of SOF and SIM in the genotype 4 pop-
ulation on the basis of genotype 4 HCV having similar susceptibil-
ity to SIM in vitro as genotype 1 and an early trial of SIM
combined with PegIFN and ribavirin showing high SVR rates in
genotype 4 patients.Safety and tolerability
Several nucleos(t)ide analogues demonstrated toxicity, resulting
in cessation of their development. Toxicity has varied and
included gastrointestinal, cardiac, hepatotoxicity and lymphope-
nia [19]. Conversely, SOF has demonstrated an excellent safety
proﬁle, both in clinical trials and clinical practice. The cumulative
data indicate that the side effect proﬁle of SOF reﬂects that of
the drugs with which it is administered. The most common side
effects associated with SOF have included fatigue, headache, nau-
sea, insomnia and anaemia [45], known side effects of RBVwith or
without interferon. As mentioned above, in the NEUTRINO study,
even with the use of PegIFN and RBV, the treatment discontinua-
tion rate was only 2% [24]. In the POSITRON study, where the con-
trol arm received placebo, the differences in adverse events
included higher fatigue and insomnia in the active treatment
arm. In addition, there was a higher incidence of anaemia in
patients in the treatment arm, thought to be due to RBV. Other-
wise, therewas no difference in laboratory abnormalities between
the two groups. In total, 2% of patients discontinued treatment in4 vol. 61 j S91–S97 S95
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the treatment arm, compared to 4% in the placebo arm [39].
Collectively, analysis from the NEUTRINO, FUSION, FISSION,
POSITRON and VALENCE trials has also shown that no individual
adverse event led to discontinuation in more than one patient
receiving SOF and RBV, and anaemia was the only adverse
event leading to discontinuation of treatment in more than
one patient receiving PegIFN, RBV and SOF [45]. Analysis from
the ION trials also conﬁrmed the safety and tolerability of SOF.
Frequent adverse events again included fatigue and insomnia,
seen in up to about a third of patients, but there were minimal
rates of discontinuation of treatment, 0–3% across all treatment
arms in each of the three trials. As seen above in the POSITRON
trial, the addition of RBV to the regimen did impart an incremental
increase in anaemia, but it tended to be mild, did not require
transfusions, and dose reduction of RBV did not impact SVR rates.Resistance
Although SOF has a high barrier to resistance, the S282T mutation
was demonstrated to be the ‘‘signature’’ resistance mutation in
in vitro studies [46]. This mutation is characterized by a marked
reduction in replicative ﬁtness [18]. It was detected transiently
in one patient receiving SOF monotherapy in the ELECTRON trial;
the patient had SVR with a repeated course of therapy with SOF
and RBV [47]. In contrast, the S282T mutation was not found in
samples from any relapser in the phase 3 development program.
The implication that retreatment of SOF failures with another SOF
containing regimen leads to SVR has been supported by recent
data on the retreatment of 14 previous SOF/RBV relapsers with
SOF and LDV as part of an arm of the NIAID SPARE study, all of
whom achieved SVR12 [48]. Similarly, 19 patients who had
relapsed after SOF/RBV +/ GS-9669 or SOF/LDV + RBV for
6 weeks received SOF/LDV + RBV for 12 weeks and all of them
achieved SVR [34]. The potential for retreatment of patients
who have failed an initial SOF containing regimen with another
SOF containing regimen without being burdened by concerns
about residual resistant variants is a distinctive characteristic of
the nucleotide polymerase inhibitor class.Conclusion
The global burden of hepatitis C is enormous but with treatment
regimens rapidly evolving, interferon no longer appears to be the
impediment to successful eradication of the virus. Nucleotide
polymerase inhibitors have demonstrated the capacity to replace
interferon as the foundation of hepatitis C treatment. The high
potency, high barrier to resistance, and pan-genotypic activity
speciﬁcally seen with SOF have given patients treatment options
that did not previously exist. In addition, the once daily dosing,
excellent safety proﬁle, short treatment durations and limited
drug-drug interactions have minimized the burden of therapy.
With the anticipated approvals of highly effective regimens con-
taining nucleotide analogues, as well as non-nucleotide based
regimens, covered elsewhere, there has been a historical para-
digm shift in the treatment of HCV. Barring constraints in access,
an important consideration which might vary geographically,
focus will shift from the traditional issue of whether to treat to
the question of what regimen to use amongst a set of choices,
offering results hitherto only imaginable. Potential drivers of
regimen selection will include differences in efﬁcacy (whichS96 Journal of Hepatology 201may be ‘‘real’’ or perceived rather than based on statistically valid
comparisons), safety and tolerability, duration, need for RBV,
availability of salvage regimens, and cost. Although there is some
suggestion from a small trial that early viral kinetics within the
ﬁrst few days of treatment may differ between patients who
achieve SVR and those that relapse [26], the phase 3 trials have
not yielded reliable predictive kinetic markers. With an 8 week
regimen seen already as a potential entry into the treatment
arena, attempts to shorten the duration of therapy even further,
while preserving efﬁcacy, might be expected, as suggested in a
pilot study which demonstrated >95% SVR12 with triple DAA reg-
imens containing SOF [49]. Even with the dramatic results from
phase 3 studies supporting the use of SOF as a backbone of ther-
apy, its use in certain treatment populations has yet to be estab-
lished. For example, patients with chronic kidney disease or on
dialysis would beneﬁt greatly from a safe, effective treatment
regimen. Additionally, further data are awaited from patients
with advanced liver disease and the post liver transplant popula-
tion. With SOF-containing regimens showing remarkably high
SVR rates in broad populations already, a role for sofosbuvir
and potentially other nucleotides appears to be ﬁrmly entrenched
in the treatment of hepatitis C.Conﬂict of interest
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